Akero Therapeutics (AKRO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

AKRO Stock Forecast


Akero Therapeutics stock forecast is as follows: an average price target of $46.00 (represents a 50.13% upside from AKRO’s last price of $30.64) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

AKRO Price Target


The average price target for Akero Therapeutics (AKRO) is $46.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $56.00 to $38.00. This represents a potential 50.13% upside from AKRO's last price of $30.64.

AKRO Analyst Ratings


Buy

According to 6 Wall Street analysts, Akero Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AKRO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Akero Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 17, 2024Ed ArceH.C. Wainwright$50.00$26.9785.39%63.19%
Jun 12, 2024Edward NashCanaccord Genuity$56.00$23.43139.01%82.77%
Jun 10, 2024Andy ChenWolfe Research$40.00$22.9973.99%30.55%
May 15, 2024Liisa BaykoEvercore ISI$38.00$20.3087.19%24.02%
Oct 11, 2023Ed ArceH.C. Wainwright$40.00$15.04165.96%30.55%
Sep 13, 2022Liisa BaykoEvercore ISI$50.00$29.0572.12%63.19%
Row per page
Go to

The latest Akero Therapeutics stock forecast, released on Sep 17, 2024 by Ed Arce from H.C. Wainwright, set a price target of $50.00, which represents a 85.39% increase from the stock price at the time of the forecast ($26.97), and a 63.19% increase from AKRO last price ($30.64).

Akero Therapeutics Price Target by Period


1M3M12M
# Anlaysts-14
Avg Price Target-$50.00$46.00
Last Closing Price$30.64$30.64$30.64
Upside/Downside-100.00%63.19%50.13%

In the current month, the average price target of Akero Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akero Therapeutics's last price of $30.64. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024Citigroup-BuyInitialise
Sep 17, 2024H.C. WainwrightBuyBuyHold
Jun 12, 2024Canaccord GenuityBuyBuyHold
Jun 10, 2024Wolfe Research-OutperformInitialise
May 15, 2024Evercore ISIOutperformOutperformHold
Sep 14, 2022Cantor Fitzgerald-OverweightInitialise
Row per page
Go to

Akero Therapeutics's last stock rating was published by Citigroup on Nov 18, 2024. The company Initialise its AKRO rating from "null" to "Buy".

Akero Therapeutics Financial Forecast


Akero Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Akero Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AKRO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Akero Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict AKRO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akero Therapeutics's previous annual EBITDA (undefined) of $NaN.

Akero Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-87.50M$-84.70M$-77.65M$-78.02M$-80.74M$-61.02M$-57.38M
High Forecast$-87.50M$-84.70M$-77.65M$-76.70M$-77.20M$-61.02M$-57.38M
Low Forecast$-87.50M$-84.70M$-77.65M$-79.34M$-84.28M$-61.02M$-57.38M
Surprise %-------

Akero Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKRO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Akero Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Akero Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AKRO last annual SG&A of $NaN (undefined).

Akero Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-1.26$-1.22$-1.12$-1.12$-1.16$-0.88$-0.83
High Forecast$-1.26$-1.22$-1.12$-1.10$-1.11$-0.88$-0.83
Low Forecast$-1.26$-1.22$-1.12$-1.14$-1.21$-0.88$-0.83
Surprise %-------

According to undefined Wall Street analysts, Akero Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKRO previous annual EPS of $NaN (undefined).

Akero Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BCELAtreca$0.09$4.004344.44%Buy
PASGPassage Bio$0.51$6.001076.47%Buy
BDTXBlack Diamond Therapeutics$2.43$14.75507.00%Buy
INZYInozyme Pharma$2.79$14.67425.81%Buy
STOKStoke Therapeutics$11.31$30.60170.56%Buy
TERNTerns Pharmaceuticals$5.60$14.25154.46%Buy
VKTXViking Therapeutics$51.53$102.4098.72%Buy
AKROAkero Therapeutics$30.64$46.0050.13%Buy
RNAAvidity Biosciences$43.65$54.5024.86%Buy
PTGXProtagonist Therapeutics$40.65$50.0023.00%Buy
RVMDRevolution Medicines, Inc. Warrant$57.07$60.636.24%Buy
MDGLMadrigal Pharmaceuticals$317.09$315.75-0.42%Buy

AKRO Forecast FAQ


Is Akero Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Akero Therapeutics (AKRO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of AKRO's total ratings.

What is AKRO's price target?

Akero Therapeutics (AKRO) average price target is $46 with a range of $38 to $56, implying a 50.13% from its last price of $30.64. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Akero Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AKRO stock, the company can go up by 50.13% (from the last price of $30.64 to the average price target of $46), up by 82.77% based on the highest stock price target, and up by 24.02% based on the lowest stock price target.

Can Akero Therapeutics stock reach $50?

AKRO's highest twelve months analyst stock price target of $56 supports the claim that Akero Therapeutics can reach $50 in the near future.

What are Akero Therapeutics's analysts' financial forecasts?

Akero Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-199M (high $-196M, low $-203M), average SG&A $0 (high $0, low $0), and average EPS is $-2.871 (high $-2.82, low $-2.922). AKRO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-328M (high $-327M, low $-329M), average SG&A $0 (high $0, low $0), and average EPS is $-4.722 (high $-4.702, low $-4.741).